FDA Panel Wants More Risk Information On Yaz Pills

Bayer’s Yaz, Yasmin contraceptive products will stay on the market. However, the FDA panel reviewing the products want more information about the possible increased risk of blood clots.

What happens now? The advisory committee made their recommendation but the final approval of the new labeling comes from the FDA itself. We will have to wait and see.

Source: FDA panel wants more risk information on Yaz pills.